招银国际：医药业关注布局思路更偏稳健低估值个股机会

智通财经2025-11-10

智通财经APP获悉，招银国际发布研报称，布局思路更偏稳健，关注低估值个股机会。固生堂(02273)、公布3亿港币回购计划，年初至今公司已累计回购3.5亿港币，回购(不含新增回购)+分红预期收益率高达7%。推荐买入三生制药(01530)、固生堂、巨子生物(02367)、药明合联(02268)、信达生物(01801)、中国生物制药(01177)。招银国际主要观点如下：MSCI中国医疗指数2025年初...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2582371841?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-10 13:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582371841","market":"sh","top_or_hot":-1,"title":"招银国际：医药业关注布局思路更偏稳健 低估值个股机会","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，招银国际发布研报称，布局思路更偏稳健，关注低估值个股机会。固生堂(02273)、公布3亿港币回购计划，年初至今公司已累计回购3.5亿港币，回购(不含新增回购)+分红预期收益率高达7%。推荐买入三生制药(01530)、固生堂、巨子生物(02367)、药明合联(02268)、信达生物(01801)、中国生物制药(01177)。招银国际主要观点如下：MSCI中国医疗指数2025年初...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1367136.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>招银国际：医药业关注布局思路更偏稳健 低估值个股机会</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n招银国际：医药业关注布局思路更偏稳健 低估值个股机会\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-10 13:43 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1367136.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，招银国际发布研报称，布局思路更偏稳健，关注低估值个股机会。固生堂(02273)、公布3亿港币回购计划，年初至今公司已累计回购3.5亿港币，回购(不含新增回购)+分红预期收益率高达7%。推荐买入三生制药(01530)、固生堂、巨子生物(02367)、药明合联(02268)、信达生物(01801)、中国生物制药(01177)。招银国际主要观点如下：MSCI中国医疗指数2025年初...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1367136.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02268","symbol_name":"药明合联","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1367136.html","article_id":"2582371841","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582371841","pubTimestamp":1762753386,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，招银国际发布研报称，布局思路更偏稳健，关注低估值个股机会。招银国际主要观点如下：MSCI中国医疗指数2025年初至今累计上涨59.5%，跑赢MSCI中国指数24.0%近期，医药板块有所回调，该行认为部分低估值个股具备吸引力。辉瑞管理层表示即将公布707的完整研发计划。此次医保谈判结果预计12月初公布。本轮集采的平均价格降幅并未公布。该行认为仿制药仍将长期维持较低利润率水平。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02268":"药明合联","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","01801":"信达生物","BK1583":"高瓴概念","SG9999014674.SGD":"Nikko AM All China Equity A SGD","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","BK1521":"挪威政府全球养老基金持仓","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1207":"个人用品","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","BK1589":"北水核心资产","SG9999004311.SGD":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD","01530":"三生制药","06978":"永泰生物-B","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","02273":"固生堂","BK1219":"保健护理服务","BK1141":"生命科学工具和服务","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","BK1191":"制药","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","BK1593":"医美概念股","BK1161":"生物科技","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","02367":"巨子生物","01177":"中国生物制药","ORR":"Militia Long/Short Equity ETF","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1515":"抗疫概念","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","BK1574":"生物医药B类股"},"translate_title":"CMB International: The pharmaceutical industry focuses on layout ideas and is more stable and low-valued stock opportunities","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02273":1,"ORR":1,"01801":1,"01177":1,"01530":1,"06978":0.7,"02268":1,"02367":1},"content_text":"智通财经APP获悉，招银国际发布研报称，布局思路更偏稳健，关注低估值个股机会。固生堂(02273)、公布3亿港币回购计划，年初至今公司已累计回购3.5亿港币，回购(不含新增回购)+分红预期收益率高达7%。推荐买入三生制药(01530)、固生堂、巨子生物(02367)、药明合联(02268)、信达生物(01801)、中国生物制药(01177)。招银国际主要观点如下：MSCI中国医疗指数2025年初至今累计上涨59.5%，跑赢MSCI中国指数24.0%近期，医药板块有所回调(MSCI中国医疗指数10月至今回调10%)，该行认为部分低估值个股具备吸引力。由于资本市场融资复苏、创新药出海交易规模上涨，国内创新药研发需求出现回暖。叠加美国降息，CXO行业有望在2H25E迎来业绩修复。已授权的创新药管线在海外的临床推进将成为创新药板块最重要的催化剂。关注已授权管线在海外的临床推进原因是：1)临床推进的确定性较高，将成为股价上涨的催化剂，2)最终的价值实现仅少部分来自授权交易的首付款，绝大部分仍需依靠品种的商业化成功带来的里程碑付款和销售分成。继续看好三生制药：目前，海外合作方辉瑞已公布707的两项全球3期临床方案，分别为联合化疗一线治疗非小细胞肺癌和联合化疗一线治疗结直肠癌。辉瑞管理层表示即将公布707的完整研发计划。三生制药在2025年SITC会议更新了PD1/VEGF联合化疗治疗一线非小细胞肺癌的2期临床数据，疗效(ORR)和安全性数据仍然显示其全球best-in-class潜力。医保谈判及第十一批集采落地，市场关注度减弱本年度医保谈判于11月初完成，共有127个目录外药品参与谈判竞价，24个药品参与商保创新药目录价格协商。此次医保谈判结果预计12月初公布。本轮医保谈判值得关注的品种包括：科伦博泰的Sac-TMT;信达生物的替妥尤单抗、KRASG12C、ROS1;康方生物的AK112、AK104;康诺亚的IL-4R单抗;荣昌生物的泰它西普、维迪西妥单抗;翰森制药的阿美替尼(辅助适应症);恒瑞医药的IL17单抗、JAK1抑制剂、HER2ADC和PCSK9单抗等。此外，第十一批集采于10月底完成，共纳入55个品种。新的集采规则聚焦“稳临床、保质量、反内卷、防围标”，医疗机构可按厂牌报量，设置“锚点价”与复活机制，引导市场良性竞争。本轮集采的平均价格降幅并未公布。此次集采保持了较高中选率，中选产品平均价差较此前批次明显缩小，说明价格竞争趋于理性。该行认为仿制药仍将长期维持较低利润率水平。由于创新药的主要投资逻辑集中在出海，因此市场对于医保谈判和集采的关注度有所减弱。但该行认为，本土市场的表现仍是重要的业绩变量。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582371841","isCrawlerRequest":true}

招银国际：医药业关注布局思路更偏稳健 低估值个股机会

精彩评论

招银国际：医药业关注布局思路更偏稳健低估值个股机会